UK-based patient recruitment and clinical-trial management business Synexus continues to make its mark in Central and Eastern Europe (CEE), acquiring three more trial centres in Poland.

The announcement closely follows a burst of activity in the CEE markets last June, when Synexus opened a regional office in Hungary, appointed a new site director in Poland and put in place a vice president, Dr Christian Tueni, to manage the company’s growing business throughout the region.

In its latest move, Synexus has completed the acquisition of CLCC, which operates three clinical trial centres in the major Polish conurbations of Warsaw, Gdynia and Katowice. The centres, which have immediately adopted the Synexus name, will work closely with the company’s “very successful” existing unit in Warsaw, it noted.

Dr Andrzej Opadczuk, the previous owner of CLCC, will continue to manage the Polish centres, reporting to Dr Tueni. Managers will be trained in the Synexus Quality Assurance System and will follow worldwide standard operating procedures.

“This acquisition provides us with access to millions more patients and a wider range of therapy areas,” said Michael Fort, chief executive of Synexus. The Synexus model of streamlined patient recruitment “continues to gain ground with our clients in pharma”, who recognise the benefits of faster trials, lower costs and improved quality, he added.

The CLCC deal brings the total number of Synexus Dedicated Research Centres to 17. According to Fort, the company is actively pursuing further acquisitions, in particular with a view to expanding its presence in India.